Buscar
-
Cerebral Hemodynamics and Levosimendan Use in Patients with Cerebral Vasospasm and Subarachnoid Hemorrhage: An Observational Perfusion CT-Based Imaging Study.
(Neurocritical Care, 2024-02-07)Article de revue -
Assisted reproductive technologies could be associated with higher risk of parenting difficulties in women with postpartum major depression
(Archives of Women's Mental Health, 2024-03-13)Article de revue -
Prevalence of suicidal thoughts and behaviors among young adults between 2000 and 2021: Results from six national representative surveys in France
(Psychiatry Research. vol. 333, pp. 115763, 2024-03-01)Article de revueLibre acceso -
Effectiveness of digital games promoting young people's mental health: A review of reviews
(Digital Health. vol. 10, pp. 20552076231220814, 2024-01-01)Article de revueLibre acceso -
Incidence and Predictors of Tuberculosis-associated IRIS in People With HIV Treated for Tuberculosis: Findings From Reflate TB2 Randomized Trial
(Open Forum Infectious Diseases. vol. 11, n° 3, pp. ofae035, 2024-03-01)Article de revueLibre acceso -
Emotion Dysregulation Is Associated With Increased Problem Cannabis Use Among Emerging Adults During COVID-19
(Journal of Studies on Alcohol and Drugs. vol. 85, n° 2, pp. 261-271, 2024-03-01)Article de revue -
European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke
(European Stroke Journal. vol. 9, n° 1, pp. 5-68, 2024-03-01)Article de revueLibre acceso -
Virological, serological and clinical outcomes in chronic hepatitis B virus infection: development and validation of the HEPA-B simulation model
(BMJ Open. vol. 14, n° 1, pp. e073498, 2024-01-12)Article de revueLibre acceso -
Anosognosia is associated with increased prevalence and faster development of neuropsychiatric symptoms in mild cognitive impairment
(Frontiers in Aging Neuroscience. vol. 16, pp. 1335878, 2024-03-06)Article de revueLibre acceso -
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
(The Lancet. vol. 403, n° 10432, pp. 1141-1152, 2024-03-07)Article de revue